Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Trovagene Company Update Wecast
 October 24, 2018
 8:30am - 9:30am EDT

Trovagene management team will provide an update on the Company's clinical development program and associated financing, key milestones, and collaboration and partnering activities.  The Webcast will take place on Wednesday, October 24th at 8:30 am EDT.  To join the conference call and webcast please click on the following link: The webcast will be available on the investor page of the Trovagene website for 90 days following the webcast presentation.